The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: Real world data from the Inflammatory Bowel Disease of the Middle East (IBD-ME) Registry group
Background: Vedolizumab is an approved ulcerative colitis (UC) treatment. Multiple large randomized clinical trials have demonstrated the drug’s efficacy and safety. However, real-world data from Middle Eastern countries are spare. The study aims to evaluate the clinical efficacy of vedolizumab (VDZ...
Saved in:
| Main Authors: | Nahla Azzam, Othman Alharbi, Mansour Altuwaijri, Yazed Alruthia, Heba Alfarhan, Suliman Alshankiti, Faris Nafisah, Qusay Ajlan, Abdulrahman Aljebreen, Majid Almadi, Mahmoud H. Mosli |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | The Saudi Journal of Gastroenterology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/sjg.sjg_249_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Effects of the Biological Agents Infliximab, Vedolizumab, and Ustekinumab on Intestinal Anastomosis: An Experimental Study in Rats
by: Alexandra Menni, et al.
Published: (2025-04-01) -
Association between vedolizumab and risk of clostridium difficile infection in patients with ulcerative colitis: A systematic review and meta-analysis
by: Maha Alghamdi, et al.
Published: (2024-11-01) -
Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis: A Real-World Retrospective Study
by: Kei Nomura, et al.
Published: (2024-09-01) -
Superior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: a real-world cohort study
by: Horng-Yih Chiu, et al.
Published: (2024-12-01) -
Colonic Lung Cancer Metastasis in Vedolizumab-Treated Immune Checkpoint Inhibitor Colitis
by: Sean S. Davis, et al.
Published: (2020-07-01)